Actinium Pharmaceuticals, Inc. (NASDAQ:ATNM)’s share price was down 3.8% on Monday . The stock traded as low as $0.25 and last traded at $0.25, approximately 24,012 shares were traded during trading. A decline of 98% from the average daily volume of 1,213,677 shares. The stock had previously closed at $0.26.
Separately, William Blair restated an “outperform” rating on shares of Actinium Pharmaceuticals in a report on Thursday, August 8th.
The company has a fifty day moving average of $0.24.
About Actinium Pharmaceuticals (NASDAQ:ATNM)
Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.
Featured Story: How Do I Invest in Dividend Stocks
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.